Beta-blockers do not reduce mortality or heart failure in patients with normal ejection fraction post-MI (ref: Kristensen doi.org/10.1056/NEJMoa2512686/)
Evolocumab significantly lowers the risk of major adverse cardiovascular events in patients without prior MI or stroke (ref: Bohula doi.org/10.1056/NEJMoa2514428/)
Rivaroxaban shows lower event rates compared to aspirin post-catheter ablation for atrial fibrillation, though not statistically significant (ref: Verma doi.org/10.1056/NEJMoa2509688/)
Remnant cholesterol is a significant independent risk factor for cardiovascular events, even in those with optimal LDL-C levels (ref: Jung doi.org/10.1016/j.jacc.2025.09.015/)
The burden of high LDL-C in China is projected to increase significantly, highlighting the need for effective management strategies (ref: Tian doi.org/10.1016/j.jacc.2025.09.1592/)
CRISPR-Cas9 gene editing targeting ANGPTL3 shows safety and potential efficacy in lipid management (ref: Laffin doi.org/10.1056/NEJMoa2511778/)
Age- and sex-specific percentiles for cardiovascular disease risk can enhance patient communication and prevention strategies (ref: Krishnan doi.org/10.1016/j.jacc.2025.09.1509/)